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Abstract
Background: S-1 (a combination of tegafur, gimeracil, and oteracil) is used to treat various cancers. Bone marrow
suppression is a dose-limiting toxicity of S-1. The relationship between relative dose intensity (RDI) and bone marrow
suppression has not been investigated. Hence, we aimed to elucidate the threshold for RDI to identify bone marrow
suppression induced by S-1.
Methods: In this retrospective cohort study, patients who initiated S-1 treatment at Tokyo Women’s Medical University,
Medical Center East between June 2015 and June 2017 were included. Bone marrow suppression induced by S-1 was
assessed using Common Terminology Criteria for Adverse Events version 4.0. The relationships between grade 3 or higher
bone marrow suppression induced by S-1 and RDIs (i.e., 70, 75, and 80%) were investigated using the multivariate Cox
proportional hazard model.
Results: We identified 143 patients in this study. The median RDI was 78.8%. Bone marrow suppression induced by S-1
developed in 19 (13.3%) patients. The multivariate Cox proportional hazard model revealed that grade ≥ 2
lymphocytopenia was associated with bone marrow suppression induced by S-1 regardless of the threshold
for RDI. In addition, RDI > 75% [hazard ratio (HR) = 1.71, p < 0.05] and RDI > 80% (HR = 1.65, p < 0.05) were associated
with bone marrow suppression induced by S-1.
Conclusions: Reduced dose of S-1 still has the risk of developing bone marrow suppression. Clinicians should assess
RDI to identify high risk patients with bone marrow suppression induced by S-1.
Keywords: S-1, Bone marrow suppression, Relative dose intensity, Lymphocytopenia
Introduction
S-1 is used for the treatment of gastric, colorectal, and
lung cancer [1–3]. S-1 consists of tegafur, gimeracil, and
oteracil in a molar ratio of 1:0.4:1 [4]. Tegafur is a pro-
drug of 5-fluorouracil (5-FU), whereas gimeracil and
oteracil act to increase the concentration of 5-FU and
reduce gastrointestinal toxicity by inhibiting dihydropyr-
idine dehydrogenase and orotate phosphoribosyltransfer-
ase, respectively [5, 6]. Because the pharmacokinetics of
5-FU and gimeracil depends on creatinine clearance,
5-FU can accumulate in patients with renal impairment
[7]. Thus, S-1 dosages are adjusted according to creatin-
ine clearance and body surface area (BSA) [8].
Bone marrow suppression is a dose-limiting toxicity of
S-1 that can result in dose reduction, prolongation of
the washout period, and discontinuation of S-1. In fact,
the occurrence of bone marrow suppression depends on
the level of exposure to chemotherapeutic agents [9].
Relative dose intensity (RDI) is a marker of the exposure
of chemotherapeutic agents, and RDI > 80% is associated
with anti-tumor effects of S-1 [10, 11]. However, there
are limited data regarding the relationship between bone
marrow suppression induced by S-1 and RDI. Therefore,
we hypothesize that the relevance between the incidence
of bone marrow suppression and RDI will be helpful to
distinguish clinically high-risk patients with bone mar-
row suppression induced by S-1.
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Hence, the aim of this study was to investigate the re-
lationship between bone marrow suppression induced by
S-1 and threshold for RDI.
Patients and methods
Study design and patients
This study was a single-center retrospective cohort
study. All patients who initiated S-1 treatment between
June 2015 and June 2017 at Tokyo Women’s Medical
University, Medical Center East, were included. Patients
who lacked data on complete blood count or RDI due to
unknown BSA were excluded. We could not calculate
the sample size before the study began because the study
was retrospective and unable to retrieve the intended
number of patients from sufficient study population who
initiated S-1 treatment in our hospital. The study proto-
col was approved by the institutional review board at
Tokyo Women’s Medical University Hospital (#4467)
prior to initiation of the study.
Data collection
We extracted patients’ demographic data from electronic
medical records. Their demographic data included back-
ground information (gender, age, height, body weight, body
mass index [BMI], and BSA), clinical laboratory data (white
blood cell [WBC] count, absolute neutrophil count [ANC],
absolute lymphocyte count [ALC], hemoglobin [Hb], plate-
let count [Plt], aspartate transaminase [AST], alanine ami-
notransferase [ALT], total bilirubin, serum albumin, serum
creatinine, and estimated glomerular filtration rate [eGFR]),
indication for S-1 treatment (gastrointestinal, lung, breast,
or the other cancers), clinical cancer stage (≥III), details of
S-1 treatment (RDI and the presence of combination
chemotherapy), and prior history of cytotoxic chemother-
apy. eGFR was calculated by prediction equation optimized
for Japanese population [12]. RDI was calculated as the ra-
tio of actual dose intensity to planned dose intensity.
Outcome
Bone marrow suppression induced by S-1 was defined as
the occurrence of grade 3 or higher hematologic adverse
events during S-1 treatment in accordance with the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 4.0 [13]; leukopenia (< 20.0 × 102/μL), neutropenia
(< 10.0 × 102/μL), lymphocytopenia (< 5.0 × 102/μL), anemia
(< 8.0 g/dL), and thrombocytopenia (< 5.0 × 104/μL). The
follow-up duration was defined as the time from initiation
of S-1 treatment to termination of S-1 treatment or the oc-
currence of bone marrow suppression.
Data analysis
Kaplan–Meier curves for the cumulative incidence of bone
marrow suppression induced by S-1 were stratified by RDI
and compared using the log-rank test. The threshold for
RDI was examined using three definitions (> 70% or ≤ 70,
> 75% or ≤ 75, and > 80% or ≤ 80%).
A multivariate Cox proportional hazard model was used
to assess the relationship between bone marrow suppres-
sion induced by S-1 and RDI. The dependent and inde-
pendent variables were defined as grade ≥ 3 of bone
marrow suppression induced by S-1 and patient charac-
teristics at the initiation of S-1 treatment, respectively.
Grade ≥ 2 of bone marrow suppression (i.e., leukopenia [<
30.0 × 102 /μL], neutropenia [< 15.0 × 102 /μL], lymphocy-
topenia [< 8.0 × 102 /μL], anemia [< 10.0 g/dL], and
thrombocytopenia [< 7.5 × 104 /μL] defined by CTCAE
version 4.0 [13]) at the initiation of S-1 treatment were
categorized as binominal variables. Indications for S-1
treatment were categorized as gastrointestinal cancer and
non-gastrointestinal cancer. Three definitions were used
for the thresholds for RDI (> 70% or ≤ 70, > 75% or ≤ 75,
and > 80% or ≤ 80%) and three final models were con-
structed accordingly.
We selected potential independent variables with p < 0.1
by univariate Cox proportional hazard analysis for multi-
variate Cox proportional hazard analysis. When there was
multicollinearity between any of the variables, we selected
one of them in the light of clinical relevance. Independent
variables for the multivariate Cox proportional hazard
model were determined using a stepwise forward selection
method according to the Akaike information criterion.
Continuous data are represented as mean and stand-
ard deviation (SD) or median and interquartile range
(IQR), and categorical data are represented as percent-
age. Hazard ratios (HR) and the 95% confidence interval
(95% CI) for bone marrow suppression induced by S-1
were calculated by Cox proportional hazard analysis. A
p < 0.05 was regarded as statistically significant unless
otherwise noted. Statistical analyses were performed
using JMP® pro 13 (SAS Institute Inc., Cary, NC, USA).
Results
Study patients
In total, 200 patients have initiated S-1 treatment during
study period at Tokyo Women’s Medical University,
Medical Center East. We excluded 47 patients who
lacked data on complete blood count and 10 patients
who could not calculate RDI. Thus, we identified 143
patients who fulfilled the inclusion criteria. Their demo-
graphic data are shown in Table 1. Males accounted for
92 (64.3%) of all patients; the mean age (SD) was 67.2
(10.6) years. The numbers of patients with grade ≥ 2
leukopenia, neutropenia, lymphocytopenia, and anemia
at initiation of S-1 treatment were 6 (4.2%), 5 (3.5%), 7
(4.9%), and 12 (8.4%), respectively. No patients had
grade ≥ 2 thrombocytopenia at the initiation of S-1 treat-
ment. The majority of patients had gastrointestinal can-
cer. The median RDI (IQR) was 78.8 (70.7–85.8) %.
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Patients with RDI > 70, > 75, and > 80% were 113
(79.0%), 85 (59.4%), and 68 (47.6%), respectively. There
were 52 (36.4%) and 51 (35.7%) patients who had prior
history of cytotoxic chemotherapy and who received
combination chemotherapy, respectively, in overall study
population. When we stratified the population by RDI of
70, 75, and 80%, patients categorized in the higher RDI
showed significantly higher rate of combination therapy
in every cutoff RDI (70%: 40.7% vs 16.7, 75%: 43.5% vs
24.1, 80%: 50.0% vs 22.7%). Besides, there were no sig-
nificant interactions with the prior history of cytotoxic
chemotherapy.
Outcome
Bone marrow suppression induced by S-1 was identified
in 19 (13.3%) patients. Grade ≥ 3 leucopenia developed in
2 (10.5%) of the 19 patients. Grade ≥ 3 neutropenia, lym-
phocytopenia, and anemia developed in 7 (36.8%) of the
19 patients. No patient had grade ≥ 3 thrombocytopenia.
The median (IQR) follow-up duration was 42 (14–175)
days.
RDI > 70% did not significantly affect the cumulative
incidence of bone marrow suppression induced by S-1
(Model 1, p = 0.10; Fig. 1a). Patients with RDI > 75% had
a higher cumulative incidence of bone marrow suppres-
sion induced by S-1 compared to RDI ≤75% (Model 2, p
< 0.05; Fig 1b). RDI > 80% had no effect on the cumula-
tive incidence of bone marrow suppression induced by
S-1 (Model 3, p = 0.09; Fig. 1c).
Data analysis
Univariate Cox proportional hazard model analysis re-
vealed that grade ≥ 2 lymphocytopenia, total bilirubin, RDI
> 70%, RDI > 75%, RDI > 80%, and presence of combin-
ation chemotherapy were associated with bone marrow
suppression induced by S-1 (Table 2). Using a stepwise
forward selection method, three final models were deter-
mined stratified by three thresholds for RDI. Bone marrow
suppression induced by S-1 was associated with grade ≥ 2
lymphocytopenia in all three final models (Table 3). Al-
though RDI > 70% (Model 1) has no significant effect on
bone marrow suppression induced by S-1, RDI > 75 and >
80% (Model 2 and 3) have a significant effect on bone
marrow suppression induced by S-1 (Table 3).
Discussion
This study revealed that bone marrow suppression in-
duced by S-1 was associated with not only grade ≥ 2
lymphocytopenia at baseline, but also RDI > 75% and
RDI > 80%. RDI > 75 and > 80% is useful to identify pa-
tients at a high risk of developing grade ≥ 3 of bone mar-
row suppression by S-1. When we used grade ≥ 2 of
bone marrow suppression as dependent variables, sig-
nificant relationships between the outcomes and any
clinical variables, including RDIs, could not be detected
(data not shown). Therefore, our study results should be
interpreted as predictors of an only severe bone marrow
suppression by S-1.
Leucopenia and lymphocytopenia have been identified
as predictors of bone marrow suppression for a number
Table 1 Demographic data
Characteristics (Number = 143) Values
Patient background
Male (%) 92 (64.3)
Age (years) 67.2 ± 10.6
Height (cm) 160.7 ± 9.3
Body weight (kg) 53.5 ± 11.3
BMI (kg/m2) 20.7 ± 3.8
BSA (m2) 1.54 ± 0.18
Clinical laboratory data
WBC (×102/μL) 53.0 [44.0–70.0]
ANC (×102/μL) 35.0 [23.0–54.0]
ALC (×102/μL) 25.3 [14.8–33.0]
Hb (g/dL) 11.9 ± 1.5
Plt (×104/μL) 21.4 [17.7–26.5]
AST (IU/L) 22.0 [18.0–31.0]
ALT (IU/L) 16.0 [11.0–24.0]
Total bilirubin (mg/dL) 0.6 [0.5–0.9]
Serum albumin (g/dL) 3.8 [3.5–4.1]
Serum creatinine (mg/dL) 0.7 [0.6–0.8]
eGFRa (mL/min/1.73 m2) 78.1 ± 21.5
Indication for S-1 treatment
Gastrointestinal cancer (%) 110 (76.9)
Lung cancer (%) 9 (6.3)
Breast cancer (%) 9 (6.3)
Other cancers (%) 15 (10.5)
Clinical cancer stage ≥III (%) 96 (67.1)
Details of S-1 treatment
RDIb (%) 78.8 [70.7–85.8]
RDIb > 70% (%) 113 (79.0)
RDIb > 75% (%) 85 (59.4)
RDIb > 80% (%) 68 (47.6)
Presence of combination chemotherapy (%) 51 (35.7)
Prior history of cytotoxic chemotherapy (%) 52 (36.4)
Continuous data are expressed as mean ± SD or median [IQR] as appropriate.
Categorical data are expressed as number (%)
SD standard deviation, IQR interquartile range, BMI body mass index, BSA body
surface area, WBC white blood cell count, ANC absolute neutrophil count, ALC
absolute lymphocyte count, Hb hemoglobin, Plt platelet count, AST aspartate
transaminase, ALT alanine aminotransferase, eGFR estimated glomerular
filtration rate, RDI relative dose intensity
aeGFR was calculated using a prediction equation
bRDI is the ratio of the actual dose intensity to the planned dose intensity
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of cytotoxic chemotherapy regimens [14–16]. Moreover,
lymphocytopenia is risk factors for bacteremia and the
severity of clinical course in cancer patients [17]. Our re-
sults indicated that grade ≥ 2 lymphocytopenia at base-
line is associated with bone marrow suppression induced
by S-1, which are consistent with the results of previous
studies on cytotoxic chemotherapy [15]. Furthermore,
grade ≥ 1 leucopenia and neutropenia are associated with
improved chemotherapeutic outcomes [18, 19]. How-
ever, lymphocytopenia is associated with poor chemo-
therapeutic outcomes [20]. Therefore, lymphocytopenia
may be associated with the reduced efficacy and toler-
ability of S-1 treatment for unknown reasons.
Focusing on anti-tumor effect of fluoropyrimidine de-
rivatives, RDI > 70 and > 89.5% have shown significantly
better relapse-free survival in colon and gastric cancer
compared with that of ≤70 and ≤ 89.5% [21, 22]. Our
study demonstrated that patients with RDI > 70% did
not have a high incidence of bone marrow suppression
induced by S-1. Despite that patients categorized in the
higher RDI had a higher rate of receiving combination
chemotherapy in this study and that a combination
chemotherapy could increase the risk of adverse drug
events during chemotherapy in general, our stepwise
Cox proportional hazard analyses failed to detect this
factor as a significant independent variable of developing
bone marrow suppression induced by S-1. Therefore,
RDI of 70 to 75% may be a reasonable option for pa-
tients who cannot tolerate S-1irrespective of patient’s
history and regimen of chemotherapy.
High RDI clinically correlates with better prognosis of
various cancers [10, 14]. Focusing on S-1, RDI > 80% is
associated with better prognosis [11]. Our study indi-
cated that RDI > 75 and > 80% are associated with bone
marrow suppression induced by S-1. This result was
maintained when a median RDI (78.8%) was used as an
independent variable instead of the RDIs of > 75 and >
80% (data are not shown). The incidence of bone
a
c
b
Fig. 1 Kaplan–Meier curves for the cumulative incidence of bone marrow suppression induced by S-1. The curves were analyzed using a log-rank
test. The x- and y-axes represent the number of days after initiation of S-1 and the cumulative incidence of bone marrow suppression induced by
S-1, respectively. Number at risk was shown below x- axis. RDI is the ratio of the actual dose intensity to the planned dose intensity. RDI, Relative
dose intensity. a. Kaplan–Meier curves for the cumulative incidence of bone marrow suppression induced by S-1 in patients with RDI > 70% and
RDI ≤70% (Model 1). Solid and dotted lines represent RDI > 70% and RDI ≤70%, respectively. b. Kaplan–Meier curves for the cumulative incidence
of bone marrow suppression induced by S-1 in patients with RDI > 75% and RDI ≤75% (Model 2). Solid and dotted lines represent RDI > 75% and
RDI ≤75%, respectively. c. Kaplan–Meier curves for the cumulative incidence of bone marrow suppression induced by S-1 in patients with RDI >
80% and RDI ≤80% (Model 3). Solid and dotted lines represent RDI > 80% and RDI ≤80%, respectively
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marrow suppression induced by S-1 is reported to be
higher in previous clinical trials than that observed in
our study (> 20% vs 13.3%) [1–3], probably because me-
dian RDI is also higher in these previous studies than in
our study (> 90% vs 78.8%). Kim et al. reported that a
decreased RDI was related to poor disease-free survival
in patients with stage II-IV gastric cancer and the haz-
ard ratios for relapse and death in the S-1-completion
group were significantly lower than those in the discon-
tinuation group [23]. In addition, Kawazoe et al. re-
ported that overdose of S-1 is associated with
discontinuation of treatment [23]. Therefore, first dose
of S-1 should be optimized to each patient to complete
S-1 treatment. In our study, the cutoff value of RDI to
prevent bone marrow suppression was 75%, thus it
might be reasonable that we decide to give 75% RDI of
S-1 as an initial dose for patients who do not require
intensive S-1 treatment (e.g., adjuvant chemotherapy
for stage I cancer).
There were several limitations in this study. First, this
was a retrospective study and the sample size was lim-
ited. In addition, since data were recorded in electronic
medical records, missing data was an inevitable limita-
tion. Second, we did not analyze performance statuses
and body temperatures, so the influence of performance
status and the incidence of febrile neutropenia could not
be assessed. Third, although subsets of lymphocytes are
associated with cytotoxic chemotherapy-induced neutro-
penia [24], there were no data on lymphocyte subsets in
our study population. Fourth, the other definitions of
RDI used in other clinical studies [25, 26] (i.e., 85, 90,
and 95%) could not be assessed because the number of
patients with RDI > 85% was limited. Fifth, we studied a
limited number of patients with renal failure. Thus, it
was difficult to evaluate the relationship between renal
function and bone marrow suppression induced by S-1.
Finally, our study did not include any data on genetic
polymorphisms that influence the efficacy and tolerabil-
ity of S-1.
Conclusions
In summary, grade ≥ 2 lymphocytopenia and high RDI
have a significant impact on bone marrow suppression
induced by S-1. Further study is needed to evaluate the
influence of RDI considering the risk-benefit profile of
S-1 treatment.
Table 2 Univariate Cox proportional hazard model of bone
marrow suppression induced by S-1
Variables HR 95% CI p value
Male gender 1.11 0.77–1.64 0.58
Age (years) 0.99 0.97–1.01 0.27
Height (cm) 1.01 0.99–1.03 0.57
Body weight (kg) 1.01 0.99–1.02 0.41
BMI (kg/m2) 1.02 0.97–1.07 0.50
BSA (m2) 1.50 0.53–4.19 0.44
Grade≥ 2 leukopeniaa 0.78 0.24–1.86 0.61
Grade≥ 2 neutropeniaa 0.66 0.20–1.61 0.39
Grade≥ 2 lymphocytopeniaa 3.79 1.31–8.78 < 0.05
Grade≥ 2 anemiaa 0.71 0.30–1.41 0.35
AST (IU/L) 1.00 0.99–1.01 0.91
ALT (IU/L) 1.00 0.99–1.01 0.76
Total bilirubin (mg/dL) 0.65 0.40–0.99 < 0.05
Serum albumin (g/dL) 0.78 0.50–1.24 0.29
eGFRb (mL/min/1.73 m2) 1.00 0.99–1.01 0.98
Gastrointestinal cancer 1.09 0.71–1.64 0.68
Clinical cancer stage ≥III 0.99 0.64–1.60 0.97
RDIc > 70% 1.54 0.99–2.48 < 0.05
RDIc > 75% 1.52 1.05–2.21 < 0.05
RDIc > 80% 1.39 0.97–1.99 0.07
Presence of combination chemotherapy 1.46 0.99–2.13 0.06
Prior history of cytotoxic chemotherapy 1.21 0.82–1.74 0.34
HR hazard ratio, 95% CI 95% confidence interval, BMI body mass index, BSA
body surface area, AST aspartate transaminase, ALT alanine aminotransferase,
eGFR estimated glomerular filtration rate, RDI relative dose intensity
aGrade ≥ 2 leukopenia, neutropenia, lymphocytopenia, anemia, and
thrombocytopenia at the initiation of S-1 treatment were assessed using
Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. No
patient had Grade ≥ 3 thrombocytopenia.
beGFR was calculated using a prediction equation.
cRDI is the ratio of the actual dose intensity administered and the planned
dose intensity.
Table 3 Multivariate Cox proportional hazard model of bone marrow suppression induced by S-1
Variables Model 1 (with RDIb > 70%) Model 2 (with RDIb > 75%) Model 3 (with RDIb > 80%)
HR 95% CI p value HR 95% CI p value HR 95% CI p value
Grade≥ 2 lymphocytopeniaa 3.93 1.35–9.11 < 0.05 5.17 1.72–12.6 < 0.01 4.75 1.60–11.4 < 0.01
RDIb > 70% 1.42 0.88–2.38 0.16 – – – – – –
RDIb > 75% – – – 1.71 1.10–2.72 < 0.05 – – –
RDIb > 80% – – – – – – 1.65 1.07–2.54 < 0.05
HR Hazard ratio, 95% CI 95% confidence interval, RDI relative dose intensity
aGrade ≥ 2 lymphocytopenia at the initiation of S-1 treatment was assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
bRDI is the ratio of the actual dose intensity to the planned dose intensity.
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